论文部分内容阅读
自1971年Thomas等首次报道造血干细胞移植(HSCT)能够使白血病患者长期存活以来,HSCT已成为恶性或难治性血液病最有效的根治性治疗方法之一。但移植物抗宿主病(GVHD)目前仍然是造成移植失败和移植相关死亡的主要因素。
Since the first report of hematopoietic stem cell transplantation (HSCT) in 1971 by Thomas et al. That long-term survival of leukemia patients, HSCT has become one of the most effective radical treatment of malignant or refractory hematological diseases. However, graft-versus-host disease (GVHD) remains the major cause of graft failure and graft-related deaths.